A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY, PK, AND BIOMARKER EFFECTS OF PTC857 IN ADULT SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS (CARDINALS) - CARDINALS

PTC Therapeutics, Inc.0 个研究点目标入组 258 人开始时间: 2022年9月27日最近更新: 2024年5月21日

试验速览

暂无简介。

•1. Males or females aged between 18 and 70 years with a body mass index (BMI) between 18 and 35 kg/m2
•2. ALS with preserved function, defined as:
•a. Onset of the first symptom leading to the diagnosis of ALS =7 and =18 months at the time of the initial Screening Visit
•b. Revised El Escorial criteria of either:
•(i) Clinically definite ALS
•(ii) Clinically probable ALS
•3. A total ALSFRS-R score of at least 34 at the start of the Screening Period
•4. No significant respiratory compromise as evidenced by slow vital capacity =60%
•5. All concomitant medications (both prescription and over the counter [OTC]) and non pharmacologic therapy regimens should be stable and unchanged from 30 days prior to the start of the Screening Period and intend to remain stable and unchanged throughout the course of the study.
•6. Female subjects must have a negative breast cancer imaging screening status (not considered clinically abnormal and/or requiring further evaluation/treatment) within 6 months prior to the Screening Visit or during the Screening Period.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 248
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•1. Females who are pregnant or nursing or plan to become pregnant during the study
•2. Subjects with clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular/ischemic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results
•3. Any clinically significant medical or psychiatric condition or medical history that, in the opinion of the investigator or the medical monitor, would interfere with the subject’s ability to participate in the study or increase the risk of participation for that subject
•4. Current participation in any other investigational study with an investigational product or participation within 30 days prior to the start of the Screening Period or 5 half-lives of the previously taken investigational drug, whichever is longer
•5. Subject has previously received PTC857
•6. Edaravone treatment, where applicable, within 30 days prior to the start of the Screening Period
•7. For female subjects, any past medical history of breast cancer, regardless of remission status, or any first degree relative with history of breast cancer

发起方